Research Article

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps

Table 5

Reference-case results.

Outcome (per patient)Predementia cohort ( )Dementia cohort ( )
Usual careFlorbetabenNetUsual careFlorbetabenNet

Survival, years6.846.940.104.574.570.00
Time to confirmed diagnosis, months4.642.49−2.155.082.66−2.42
Time in predementia, years3.223.560.34N/AN/AN/A
Time to institutional care, years5.485.720.243.173.290.12
Time in severity, years
 Mild3.533.820.290.560.600.04
 Mildly moderate0.460.44−0.020.770.780.01
 Moderate 0.48 0.45 −0.03 0.71 0.71 0.00
 Moderately severe 0.42 0.40 −0.01 0.57 0.56 −0.01
 Severe 1.96 1.83 −0.13 1.96 1.92 −0.05
Caregiver time, years 0.92 0.91 −0.01 0.77 0.76 −0.01
Costs (discounted)
 Total direct medical care$301,599$289,225−$12,374$314,156$303,070−$11,086
 Caregiver time$47,914$47,271−$643$42,311$42,008−$303
 Total $349,514$336,496−$13,018$356,466$345,077−$11,389
QALYs (discounted)
 Patients3.533.680.151.751.780.03
 Caregivers4.294.410.122.592.600.01
 Total7.828.090.274.344.370.03
ICERs (discounted)
 PatientsDominantDominant
 CaregiversDominantDominant
 TotalDominantDominant

QALYs: quality-adjusted life years; ICERs: incremental cost-effectiveness ratios.
Note: inconsistency may occur due to rounding.